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INTRODUCTION
As the part of research about the cost of health care system, 
there has been a growing interest worldwide over the last 
ten years in estimating the cost of illness [1­7] with most 
of studies covering only particular diseases [8­16], injuries 
[17], disorders [18] or conditions [19­24]. Their expressed 
value represents the burden that a particular disease or 
group of diseases puts on the society [5]. The first stud­
ies related to the cost of treatment of a disease or group 
of diseases occurred in 1950s, but until 2000, when the 
Organization for Economic Development countries (OECD) 
established a “system of health care”, there was no meth­
odological framework for calculating the operating cost 
of the particular illness.
Table 6 in the System of Health Accounts (SHA) [25], 
as the part of National Health Accounts (NHA), shows a 
running costs of health care by main groups of diseases 
according to the International Classification of Diseases 
(ICD­10), here presented in Table 1.
In SHA health care costs by ICD­10 categories are 
defined as all those costs in health system that do not 
include prevention, public health services, health admin­
istration, health insurance, as well as functions related to 
health care.
The aim of this study was to determine the cost of 
health care in Serbia by main groups of the ICD­10, and 
to allow comparative analysis of cost for the treatment of 
the group of diseases in the period from 2004 to 2009.
SUMMARY
Introduction As the part of research on costs in the health care system, there is a growing interest in the world for 
the estimating costs for the treatment of disease. This value represents the burden that a particular disease or group 
of diseases puts on the society. Until the year 2000, when the Organization for Economic Countries Development 
(OECD) established a System of Health Accounts (SHA), there was not even approximate methodological guide for 
calculating the cost of the disease. The aim of this study was to determine the costs of health care in the Republic of 
Serbia according to the major International Classification of Diseases (ICD-10) and to provide a comparative cost anal-
ysis for the treatment of diseases in the period from 2004 to 2009.
Material and Methods A retrospective and comparative analysis of health statistics from the database of the Institute 
of Public Health of Serbia and financial information provided by the Health Insurance Fund in the period 2004–2009 
was performed. Financial information and data on hospital services, outpatient, home health care, ancillary health 
care services, drug consumption and consumer goods in healthcare were analyzed using SHA methodology.
Results Results showed that during the observation period, the maximum cost of health care in Serbia by main clas-
sification of ICD-10 was achieved in 2009 and it was RSD 144,150,456,906.00 (€ 1,503,321,134; $ 2,160,253,219) and the 
minimal cost was achieved in 2004 – the amount being RSD 49,546,211,470.00 (€ 628,086,723; $ 855,203,134). Results 
showed that in 2004 the highest costs were allocated to circulatory diseases (18.98%), followed by neoplasm (11.12%), 
and lowest for congenital anomalies (0.64%). In 2009, the highest costs were allocated to circulatory diseases (18.87%), 
infectious and parasitic diseases (11.20%), diseases of digestive system (9.26%) nervous system diseases (9.20%), and 
neoplasm (8.88%), whereas the minimal funds were allocated for congenital anomalies (0.33%).
Conclusion Comparative analysis showed that the value of overall spending in healthcare increased three times in 
2009 as compared to 2004.
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•	 H.C.1.3. Financial resources spent for outpatient 
patients treatment by ICD­10 were obtained by multi­
plying the number of outpatient treatment services 
(source: Institute of Public Health of Serbia) with the 
price of the current HIF Price List for health services.
•	 H.C.1.4. Home health services were expressed as home 
services treatment (data source table planning for 
health, which deal with the Institute of Public Health 
of Serbia) multiplied by the price of the current HIF 
Price List for health services.
•	 H.C.4. Ancillary health care services (laboratory, 
diagnostic and patient transportation) are financially 
expressed by the empirically estimated total number 
of services by groups of diseases, and then multiplied 
by the respective prices of the current HIF Price List 
for health services.
•	 H.C.5.1. Financial statements on items “Drugs and 
other consumer goods” according to groups of diseases 
by ICD­10, were obtained from the Drugs and Medical 
Devices Agency of Serbia.
Collected items H.C.1., H.C.1.2., H.C.1.3., H.C.1.4., 
H.C.4. and H.C.5.1., by groups of diseases express the esti­
mated financial value of the total cost of health care for 
diseases according to the ICD­10.
The comparative and retrospective methods of research 
were used for the analysis.
When making this analysis, the data from the 
Republican Statistical Office (RSO) and the National Bank 
of Serbia (NBS) were applied.
RESULTS
The results have determined the costs for health care by 
main ICD­10 groups (Table 2). The results are shown in 
Graphs 1­12 with a special analysis for each year.
The analysis showed that total cost for health 
care by main ICD­10 categories in 2004 amounted 
49,546,621,147.00 RSD (€ 628,086,723; $ 855,203,134). 
By groups of diseases the highest costs were allocated 
to circulatory diseases (18,98%), followed by neoplasm 
(11.12%) and diseases of urogenital system (10.02%), 
where the minimal funds were allocated for congeni­
tal anomalies (0.64%) and prenatal conditions (0.86%) 
(Graphs 1 and 2). Health care expenditures by main 
Table 2. Total costs for health care according to the ICD-10 groups in 
Serbia from 2004 to 2009
Tabela 2. Ukupni troškovi zdravstvene zaštite prema grupama MKB 











2004 49,546,621,147.00 628,086,723 855,203,134
2005 81,222,190,366.00 949,967,138 1,124,666,678
2006 96,162,554,246.00 1,217,247,522 1,603,358,597
2007 120,987,502,236.00 1,526,922,066 2,251,868,727
2008 142,398,620,728.00 1,607,189,769 2,263,889,041
2009 144,150,456,906.00 1,503,321,134 2,160,253,219
Source: NBS and PHIS Izvor: NBS i IZJZS
Table 1. Groups of diseases according to the International Classifi-
cation of Diseases (ICD-10) using the methodology for table 6 SHA 
on the basis SHA Version 1.
Tabela 1. Raspodela grupa oboljenja prema Međunarodnoj klasifika-






A00-B99 Infectious and parasitic diseasesInfektivne i parazitske bolesti
C00-D48 NeoplasmTumori
E00-E90 Endocrine and metabolic diseasesEndokrine i bolesti metabolizma
D50-D89 Blood diseasesBolesti krvi
F00-F99 Mental disordersMentalni poremećaji
G00-G99 Diseases of the nervous systemBolesti nervnog sistema
I00-I99 Vascular diseasesBolesti krvotoka
J00-J99 Respiratory diseasesBolesti disajnog sistema
K00-K93 Digestive diseasesBolesti digestivnog sistema
N00-N99 Diseases of the genitourinary systemBolesti urogenitalnog sistema
O00-O99 Complications of pregnancy/childbirthKomplikacije trudnoće i porođaja
L00-L99 Skin and subcutaneous tissue diseasesBolesti kože i potkožnog tkiva
M00-M99 Diseases of the musculoskeletal systemBolesti mišićno-koštanog sistema
Q00-Q99 Congenital anomaliesUrođene anomalije
P00-P96 Perinatal conditionsPerinatalna stanja
R00-R99 Symptoms and pathological conditionsSimptomi i patološka stanja
S00-T98 Injuries, poisoning and consequencesPovrede, trovanja i posledice
V01-Z99 All other categoriesSve ostale kategorije
MATERIAL AND METHODS
Retrospective and comparative analysis of health statis­
tics from the Institute of Public Health of Serbia (IPH) 
database and financial data from the National Health 
Insurance Fund (NHIF) in the period from 2004 to 2009 
was performed. Financial information and data on hospi­
tal services, outpatient, home health care, ancillary health 
care services, drug consumption and consumer goods in 
health were analyzed according to the methodology of 
NHA and the OECD manual, SHA Version 1.0.
Health care costs of the population of Serbia by the 
main ICD­10 categories were calculated according to the 
following NHA schedule and OECD methodology:
•	 H.C.1. Hospital services are financially expressed by the 
number of hospital days (hd.) according to the disease 
groups (source: Institute of Public Health of Serbia) 
multiplied with the price of the current HIF Price List 
for hospital services [26].
•	 H.C.1.2. Day care services are not registered by groups 
of diseases (no data).









































































































Graph 1. Costs in Euros for healthcare by ICD-10 groups in 2004













































































































Groups of diseases (ICD-10)
Grupe bolesti (MKB)
Graph 2. Costs in US dollars for healthcare by ICD-10 groups in 2004









































































































Groups of diseases (ICD-10)
Grupe bolesti (MKB)
Graph 3. Costs in Euros for healthcare by ICD-10 groups in 2005
Grafikon 3. Troškovi zdravstvene zaštite prema grupama oboljenja MKB u 2005. godini izraženi u evrima
Source: Republican Statistical Office (RSO), National Bank of Serbia (NBS) and Institute of Public Health of Serbia (IPHS)
Izvor: Republički zavod za statistiku (RZS), Narodna banka Srbije (NBS) i Institut za javno zdravlje Srbije (IZJZS)
Source: RSO, NBS and IPHS
Izvor: RZS, NBS i IZJZS
Source: RSO, NBS and IPHS
Izvor: RZS, NBS i IZJZS









































































































Groups of diseases (ICD-10)
Grupe bolesti (MKB)
Graph 4. Costs in US dollars for healthcare by ICD-10 groups in 2005






































































































Groups of diseases (ICD-10)
Grupe bolesti (MKB)
Graph 5. Costs in Euros for healthcare by ICD-10 groups in 2006











































































































Groups of diseases (ICD-10)
Grupe bolesti (MKB)
Graph 6. Costs in US dollars for healthcare by ICD-10 groups in 2006
Grafikon 6. Troškovi zdravstvene zaštite prema grupama oboljenja MKB u 2006. godini izraženi u američkim dolarima
Source: RSO, NBS and IPHS
Izvor: RZS, NBS i IZJZS
Source: RSO, NBS and IPHS
Izvor: RZS, NBS i IZJZS
Source: RSO, NBS and IPHS
Izvor: RZS, NBS i IZJZS







































































































Groups of diseases (ICD-10)
Grupe bolesti (MKB)
Graph 7. Costs in Euros for healthcare by ICD-10 groups in 2007














































































































Groups of diseases (ICD-10)
Grupe bolesti (MKB)
Graph 8. Costs in US dollars for healthcare by ICD-10 groups in 2007








































































































Groups of diseases (ICD-10)
Grupe bolesti (MKB)
Graph 9. Costs in Euros for healthcare by ICD-10 groups in 2008
Grafikon 9. Troškovi zdravstvene zaštite prema grupama oboljenja MKB u 2008. godini izraženi u evrima
Source: RSO, NBS and IPHS
Izvor: RZS, NBS i IZJZS
Source: RSO, NBS and IPHS
Izvor: RZS, NBS i IZJZS
Source: RSO, NBS and IPHS
Izvor: RZS, NBS i IZJZS










































































































Groups of diseases (ICD-10)
Grupe bolesti (MKB)
Graph 10. Costs in US dollars for healthcare by ICD-10 groups in 2008






































































































Groups of diseases (ICD-10)
Grupe bolesti (MKB)
Graph 11. Costs in Euros for healthcare by ICD-10 groups in 2009













































































































Groups of diseases (ICD-10)
Grupe bolesti (MKB)
Graph 12. Costs in US dollars for healthcare by ICD-10 groups in 2009
Grafikon 12. Troškovi zdravstvene zaštite prema grupama oboljenja MKB u 2009. godini izraženi u američkim dolarima
Source: RSO, NBS and IPHS
Izvor: RZS, NBS i IZJZS
Source: RSO, NBS and IPHS
Izvor: RZS, NBS i IZJZS
Source: RSO, NBS and IPHS
Izvor: RZS, NBS i IZJZS
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ICD­10 categories in 2004 per capita amounted € 83.76, 
while the percentage of total costs in relation to the gross 
domestic product (GDP) for the year 2004 was 3.58%.
The results showed that the health care cost by main 
ICD­10 categories in 2005 amounted 81,222,190,336.00 
RSD (€ 949,967,138; $ 1,124,666,678). As observed by 
groups of diseases, the highest costs were allocated to 
circulatory diseases (17.26%), infectious and parasitic 
diseases (10.46%), neoplasm (9.49%) and urogenital 
system diseases (9.33%), while the lowest allocated funds 
were for symptoms and pathological conditions (0.92%), 
congenital anomalies (0.61%) and prenatal conditions 
(0.45%) (Graphs 3 and 4). Total cost for health care by 
main ICD­10 categories per capita amounted to € 126.70 
in 2005, while the percentage of total expenditures rela­
tive to GDP for the same year was 4.81%.
Total expenditure on health care by main ICD­10 
categories in 2006 amounted 96,162,554,246.00 RSD (€ 
1,217,247,522; $ 1,603,358,597). Observed by groups of 
diseases the highest amount of funds were allocated to 
circulatory diseases (20.14%), infectious and parasitic 
diseases (11.64%), digestive system diseases (9.87%) 
and neoplasm (8.48%), with the lowest funds allocated 
for symptoms and pathological conditions (0.95%), 
congenital anomalies (0.59%) and perinatal conditions 
(0.59%) (Graphs 5 and 6). The analysis showed that cost 
of health care by main ICD­10 categories in 2006 per 
capita amounted to € 176.00, while the percentage of total 
expenses in relation to GDP for 2006 amounts to 4.86%.
Total expenditure on health care by main ICD­10 
categories in 2007 amounted 120,987,502,236.00 RSD 
(€ 1,526,922,066; $ 2,251,868,727). Observed by groups 
of diseases the highest costs were allocated to circula­
tory diseases (19.42%), infectious and parasitic diseases 
(11.67%), digestive system diseases (9.53%) and neoplasm 
(8.33%), with the lowest allocation of funds to symptoms 
and pathological conditions (0.79%), congenital anomalies 
(0.49%) and perinatal conditions (0.37%) (Graphs 7 and 
8). In 2007 the costs for health care by main ICD­10 cate­
gories per capita amounted to € 201.00, while the percent­
age of total expenses in relation to GDP for the same year 
was 5.12%.
The results showed that the total costs for health 
care by main ICD­10 categories in 2008 amounted 
142,398,620,728.00 RSD (€ 1,607,189,769; $ 2,263,889,041). 
Observed by groups of diseases the highest costs related 
to circulatory diseases (21.64%), nervous system diseases 
(8.73%), infectious and parasitic diseases (10.53%), 
diseases of digestive system (10.40%) and neoplasm 
(8.24%), while the lowest costs related to symptoms and 
pathological conditions (0.70%) and congenital anoma­
lies (0.30%) (Graphs 9 and 10). The analysis showed that 
cost of health care by main ICD­10 categories in 2008 per 
capita amounted to € 232.00, while the percentage of total 
expenses in relation to GDP for the same year amounted 
to 5.04%.
Total expenditure on health care by main ICD­10 cate­
gories in 2009 year amounted 144,150,456,906.00 RSD (€ 
1,633,396,861; $ 2,160,253,219). Observed by groups of 
diseases the highest costs were for circulatory diseases 
18.87%, followed by infectious and parasitic diseases 
11.20%, diseases of digestive system of 9.26% and 8.88% 
for neoplasm and the lowest were for isolated congeni­
tal anomalies of 0.33% (Graphs 11 and 12). The analysis 
showed that costs of health care by main ICD­10 catego­
ries in 2009 per capita amounted to € 200.00, while the 
percentage of total expenditures relative to GDP for 2009 
amounted to 5.10%.
The results showed that the greatest costs per groups 
of diseases in the period 2004–2009 were for circulatory 
diseases, and the lowest for congenital anomalies and 
perinatal conditions. The growth index funds by groups 
of diseases in this period showed the highest amount of 
funds within the period 2004–2009 allocated for blood 
diseases and they were increased five times, while fund­
ing for diseases of nervous system increased four times 
(Graph 13).
Health care expenditures by main ICD­10 catego­
ries per capita have a constant upward trend until 2008, 






























































































Graph 13. Growth index of financial resources by groups of diseases in the period 2004–2009
Grafikon 13. Indeks rasta finansijskih sredstava prema grupama oboljenja u periodu 2004–2009. godine
Source: Institute of Public Health of Serbia in the period 2004–2009 
Izvor: Institut za javno zdravlje Srbije u periodu 2004–2009.
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The percentage share of total costs for health care by 
main ICD­10 categories in GDP in the period 2004–2009 
had continuous growth from 3.58% to 5.10% (Table 4).
DISCUSSION
A review of articles dealing with estimating cost of illness 
[1­7] have shown that studies usually covered some particu­
lar disease [8­16], injuries [17], disorders [18], or conditions 
[19­24]. Costs for health care by main groups of diseases 
are shown only in table 6 of SHA [25]. Many users of NHA 
tables have considered that Table 6, entitled “Health care 
costs according to the main groups of the International 
Classification of Diseases” (ICD­10 categories) was the 
most important and useful to decision makers. Although 
there is still no internationally accepted strict method­
ological instructions for making table 6 (except for the 
framework used in this study), international comparisons 
based on Table 6, although still very rare, started to appear 
[27]. International comparability is the main advantage of 
Table 6, while the main disadvantage is that the cost esti­
mates in different countries vary in coverage and meth­
odology of assessment, so the estimates are based on a set 
of assumptions and/or very small samples.
Total expenditures on health care in Serbia by main 
international classifications of disease in the period from 
2004 to 2009 grew from 49,546,211,470.00 RSD in 2004 
to 144,150,456,906.00 RSD in year 2009. Costs per capita 
expressed in Euros in the period from 2004 to 2009 grew 
from 83.76 Euros per person in year 2004 to 232 Euros 
in 2008. In 2009, the costs were reduced to 200 Euros per 
person, which is explained by low value of Dinar to Euro 
in 2009. Expenditure per capita expressed in dollars in the 
observed period recorded the same trend growth.
Observed by groups of diseases the highest expenses 
in Serbia during period from 2004 to 2009 were for circu­
latory diseases (increased three times), and as compared 
to the increase in funding for other groups of diseases, 
showed the average growth. Financial resources for 
blood diseases during this period increased as much as 5 
times, while for nervous system diseases they increased 
4 times. The funds for infectious and parasitic diseases in 
this period increased four times, while for diseases of the 
musculoskeletal system increased 3 times.
When these costs were compared with findings from 
Australia, Canada, France, Germany and Netherlands 
[27] it was observed that in these countries circulatory 
diseases were credited for major expenses as well, prob­
ably as a consequence of modern life style. Unlike our 
country, where infectious and parasitic diseases proved 
the second highest consumption of financial funds in 
the observed period, followed by diseases of digestive 
system, nervous system diseases and neoplasm, in the 
above countries nervous system diseases proved to be the 
second largest consumer of financial resources, followed 
by diseases of digestive system, musculoskeletal system 
and neoplasm.
Observed by years, the total cost of health care by main 
ICD­10 categories showed the tendency of growth and 
was increased almost threefold, from 49,546,621,147.00 
in year 2004, to 144,150,456,906.00 in 2009. Faster growth 
of health care cost than growth of general public expendi­
tures for health care in the same period, which increased 
from 82,335,000,000.00 in 2004 to 181,536,000,000.00 
in 2009 was recorded [28]. This fact speaks in favour of 
growing cost in the Republic of Serbia for the treatment of 
diseases over the years, and a reduction of investments in 
prevention, public health services, health administration, 
health insurance, as well as functions related to health 
care. The percentage in share of costs for health care by 
main ICD­10 categories in GDP in the period 2004–2009 
increased from 3.58% to 5.10% in 2009.
In 2004, the share of costs for health care by main 
ICD­10 groups in Serbia was 54.1% of the total cost for 
health care, while the share in Germany in the same year 
amounted 62% and in the Netherlands 60% [27]. There 
are no data available for other countries and other years, 
thus they are not comparable.
CONCLUSION
Comparative analysis showed the highest costs for health 
care in the period from 2004 to 200 in Serbia were allo­
cated for circulatory diseases and overall spending in health 
care increased three times in 2009 as compared to 2004.
Table 4. Percentage of costs for health care in GDP from 2004 to 2009




GDP at current prices 
(in million RSD)
BDP u tekućim cenama 
(u milionima dinara)
Share of assets  
in GDP 








Source: RSO and IPHS Izvor: RZS i IZJZS
Table 3. Health care expenditures per capita from 2004 to 2009












2004 6,608 83.76 114
2005 10,833 126.7 150
2006 12,825 176 213
2007 16,136 201 300
2008 18,992 232 302
2009 19,225 200 288
Sourse: NBS and IPHS Izvor: NBS i IZJZS
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UVOD
U okvi ru is tra ži va nja tro ško va u si ste mu zdrav stve ne za šti te po­
sled njih de set go di na u sve tu vla da sve ve će in te re so va nje za iz­
ra ču na va nje tro ško va le če nja bo le sni ka [1­7]. Ne ke stu di je su 
ob ra di le sa mo po je di ne bo le sti [8­16], po vre de [17], po re me ća­
je [18] ili sta nja [19­24]. Tro ško vi zdrav stve ne za šti te pred sta­
vlja ju bre me ko jim od re đe na bo lest ili gru pa obo lje nja op te re­
ću je dru štvo [5]. Pr ve stu di je o nov ča nim iz no si ma le če nja od 
od re đe nih bo le sti ili gru pa obo lje nja po ja vi le su se 1950. go di­
ne, ali sve do 2000, ka da je Or ga ni za ci ja za eko nom ski raz voj 
dr ža va (Or ga ni sa tion for Eco no mic Co-ope ra tion and De ve lop-
ment – OECD) for mi ra la Si stem zdrav stve nih ra ču na (SZR), ni­
je po sto ja lo ni okvir no me to do lo ško uput stvo za iz ra ču na va nje 
ce ne le če nja bo le sni ka.
U ta be li broj 6 u SZR [25], kao de lu Na ci o nal nog zdrav stve­
nog ra ču na (NZR), pri ka za ni su te ku ći tro ško vi zdrav stve ne za­
šti te pre ma glav nim gru pa ma obo lje nja Me đu na rod ne kla si fi­
ka ci je bo le sti (MKB), ko je su da te u ta be li 1. U SZR su kao tro­
ško vi zdrav stve ne za šti te de fi ni sa ni svi oni tro ško vi u zdrav­
stve nom si ste mu ko ji ne uklju ču ju pre ven ci ju, uslu ge jav nog 
zdrav stva, zdrav stve nu ad mi ni stra ci ju, zdrav stve no osi gu ra nje 
i tro ško ve za vr še nje funk ci ja u ve zi sa zdrav stve nom za šti tom.
Cilj ovog ra da bio je da se utvr de tro ško vi zdrav stve ne za šti­
te sta nov ni ka Re pu bli ke Sr bi je pre ma glav nim gru pa ma obo lje­
nja MKB za pe riod 2004–2009. go di ne.
MATERIJAL I METODE RADA
Ura đe na je re tro spek tiv na i kom pa ra tiv na ana li za zdrav stve nih 
sta ti stič kih po da ta ka iz ba ze In sti tu ta za jav no zdra vlje Sr bi je 
(IZJZS) i fi nan sij skih po da ta ka Re pu blič kog za vo da za zdrav­
stve no osi gu ra nje (RZ ZO) za pe riod 2004–2009. go di ne. Fi nan­
sij ski i po da ci o uslu ga ma bol nič kog, am bu lant nog i kuć nog le­
če nja, po moć nim uslu ga ma zdrav stve ne za šti te, po tro šnji le ko­
va i po tro šnih do ba ra u zdrav stvu ana li zi ra ni su pre ma me to­
do lo gi ji SZR (ver zi ja 1.0).
Tro ško vi zdrav stve ne za šti te sta nov ni ka Sr bi je pre ma glav­
nim ka te go ri ja ma MKB ra đe ni su po sle de ćoj she mi i me to do­
lo gi ji NZR i OECD:
•	 H.C.1. – uslu ge bol nič kog le če nja su fi nan sij ski iz ra že ne ta­
ko što je broj bol nič kih da na po gru pa ma bo le sti (iz vor po­
da ta ka: IZJZS) po mno žen sa ce nom bol nič kog da na iz va že­
ćeg Ce nov ni ka zdrav stve nih uslu ga RZ ZO [26];
•	 H.C.1.2. – uslu ge dnev ne ne ge ni su re gi stro va ne po gru pa­
ma bo le sti (ni je bi lo po da ta ka);
•	 H.C.1.3. – fi nan sij ska sred stva po tro še na za am bu lant no le­
če nje bo le sni ka do bi je na su ta ko što je broj uslu ga am bu lant­
nog le če nja (iz vor po da ta ka: IZJZS) po mno žen sa ce nom iz 
va že ćeg Ce nov ni ka zdrav stve nih uslu ga RZ ZO;
•	 H.C.1.4. – uslu ge kuć nog le če nja fi nan sij ski su iz ra že ne ta­
ko što su uslu ge kuć nog le če nja (iz vor po da ta ka: plan ske ta­
be le za do mo ve zdra vlja ko je ob ra đu je IZJZS) po mno že ne 
sa ce nom iz va že ćeg Ce nov ni ka zdrav stve nih uslu ga RZ ZO;
KRATAK SADRŽAJ
Uvod U okvi ru is tra ži va nja tro ško va u si ste mu zdrav stve ne za šti te po sled njih de set go di na u sve tu je sve ve će in te re so va nje za iz-
ra ču na va nje tro ško va le če nja bo le sni ka. Ova vred nost je bre me ko jim od re đe na bo lest ili gru pa obo lje nja op te re ću je dru štvo. Do 
2000. go di ne, ka da je Or ga ni za ci ja za eko nom ski raz voj dr ža va (OECD) for mi ra la Si stem zdrav stve nih ra ču na (SZR), ni je po sto ja lo 
okvir no me to do lo ško uput stvo za iz ra ču na va nje ce ne le če nja bo le sni ka. Cilj ovog ra da bio je da se utvr de tro ško vi zdrav stve ne za-
šti te u Sr bi ji pre ma Me đu na rod noj kla si fi ka ci ji bo le sti (MKB) od 2004. do 2009. go di ne.
Ma te ri jal i me to de ra da Ura đe na je re tro spek tiv na i kom pa ra tiv na ana li za zdrav stve nih sta ti stič kih po da ta ka iz ba ze In sti tu ta za 
jav no zdra vlje Sr bi je i fi nan sij skih po da ta ka Re pu blič kog za vo da za zdrav stve no osi gu ra nje za pe riod 2004–2009. go di ne. Fi nan sij-
ski i po da ci o uslu ga ma bol nič kog, am bu lant nog i kuć nog le če nja, po moć nim uslu ga ma zdrav stve ne za šti te, po tro šnji le ko va i po-
tro šnih do ba ra u zdrav stvu ana li zi ra ni su pri me nom me to do lo gi je SZR.
Re zul ta ti To kom po sma tra nog pe ri o da naj ve ći tro šak za zdrav stve nu za šti tu ostva ren je 2009. go di ne, a iz no sio je 144.150.456.906,00 
di na ra (1.503.321.134 evra; 2.160.253.219 ame rič kih do la ra), dok je naj ma nji ostva ren 2004. go di ne, a bio je 49.546.211.470,00 di na-
ra (628.086.723 evra; 855.203.134 ame rič kih do la ra). Te go di ne naj ve ći deo tro ško va bio je iz dvo jen za le če nje od kar di o va sku lar nih 
bo le sti (18,98%) i tu mo ra (11,12%), a naj ma nji deo za le če nje oso ba s uro đe nim ano ma li ja ma (0,64%). U 2009. go di ni naj ve ći deo 
sred sta va utro šen je za le če nje od kar di o va sku lar nih obo lje nja (18,87%), in fek tiv nih i pa ra zit skih bo le sti (11,20%), obo lje nja di ge-
stiv nog si ste ma (9,26%), bo le sti ner vnog si ste ma (9,20%) i tu mo ra (8,88%), dok je naj ma nje novčanih sred sta va iz dvo je no za le če-
nje oso ba s uro đe nim po re me ća ji ma (0,33%).
Za klju čak Kom pa ra tiv na ana li za je po ka za la da su se tro ško vi zdrav stve ne za šti te sta nov ni ka Sr bi je od 2004. do 2009. go di ne po-
ve ća li čak tri pu ta.
Ključ ne re či: Me đu na rod na kla si fi ka ci ja bo le sti; zdrav stve na po tro šnja; „ko šta nje” bo le sti
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•	 H.C.4. – po moć ne uslu ge zdrav stve ne za šti te (la bo ra to rij ske 
ana li ze, di jag no sti ka i pre voz bo le sni ka) fi nan sij ski su iz ra­
že ne ta ko što je is ku stve no pro ce njen uku pan broj tih uslu­
ga po mno žen s od go va ra ju ćim ce na ma iz va že ćeg Ce nov ni­
ka zdrav stve nih uslu ga RZ ZO;
•	 H.C.5.1. – fi nan sij ski pri kaz utro ška le ko va i dru gih po tro­
šnih do ba ra do bi jen je od Agen ci je za le ko ve i me di cin ska 
sred stva Sr bi je.
Zbir stav ki H.C.1, H.C.1.2, H.C.1.3, H.C.1.4, H.C.4. i H.C.5.1. 
po gru pa ma bo le sti da je pro ce nje nu fi nan sij sku vred nost ukup­
ne ce ne zdrav stve ne za šti te sta nov ni ka Sr bi je pre ma gru pa ma 
obo lje nja MKB.
U ana li zi su pri me nje ne kom pa ra tiv na i re tro spek tiv na me­
to da is tra ži va nja. Za ana li zu su ko ri šće ni i po da ci Re pu blič­
kog za vo da za sta ti sti ku (RZS) i Na rod ne ban ke Sr bi je (NBS).
REZULTATI
Ukup na nov ča na sred stva (iz ra že na u di na ri ma, evri ma i ame­
rič kim do la ri ma) ko ja su utro še na na zdrav stve nu za šti tu sta­
nov ni ka Sr bi je to kom šest po sma tra nih go di na, pre ma glav­
nim gru pa ma obo lje nja MKB, pri ka za na su u ta be li 2. Ana li­
ze za sva ku go di nu po seb no pri ka za ne su na gra fi ko ni ma 1­12.
Ukup ni tro ško vi zdrav stve ne za šti te u 2004. go di ni bi li su 
sko ro 50 mi li jar di di na ra (oko 628 mi li o na evra; 855 mi li o na 
do la ra). Po sma tra no po gru pa ma bo le sti, naj ve ća nov ča na sred­
stva iz dvo je na su za le če nje oso ba s kar di o va sku lar nim obo lje­
nji ma (18,98%), tu mo ri ma (11,12%) i bo le sti ma uro ge ni tal­
nog si ste ma (10,02%), dok je naj ma nje sred sta va utro še no za 
le če nje bo le sni ka s uro đe nim ano ma li ja ma (0,64 %) i pe ri na­
tal nim sta nji ma (0,86%) (Gra fi ko ni 1 i 2). Tro ško vi zdrav stve­
ne za šti te po gla vi sta nov ni ka u 2004. go di ni iz no si li su 83,76 
evra, dok je udeo ukup nih tro ško va u bru to do ma ćem pro iz­
vo du (BDP) bio 3,58%.
Ukup ni tro ško vi zdrav stve ne za šti te u 2005. go di ni bi li su ne­
što ve ći od 81 mi li jar de di na ra (oko 950 mi li o na evra; oko mi­
li jar du i 125 mi li o na do la ra). Po sma tra no po gru pa ma bo le sti, 
naj ve ća nov ča na sred stva iz dvo je na su za le če nje oso ba s kar di­
o va sku lar nim obo lje nji ma (17,26%), in fek tiv nim i pa ra zit skim 
bo le sti ma (10,46%), tu mo ri ma (9,49%) i bo le sti ma uro ge ni tal­
nog si ste ma (9,33%), dok je naj ma nje sred sta va utro še no na le­
če nje simp to ma i pa to lo ških sta nja (0,92%), uro đe nih ano ma li ja 
(0,61%) i pe ri na tal nih sta nja (0,45%) (Gra fi ko ni 3 i 4). Tro ško vi 
zdrav stve ne za šti te po gla vi sta nov ni ka u 2005. go di ni iz no si li 
su 126,70 evra, dok je udeo ukup nih tro ško va u BDP bio 4,81%.
Ukup ni tro ško vi zdrav stve ne za šti te u 2006. go di ni bi li su 
ne što ve ći od 96 mi li jar di di na ra (1,22 mi li jar de evra; 1,6 mi­
li jar di do la ra). Po sma tra no po gru pa ma bo le sti, naj ve ća nov­
ča na sred stva iz dvo je na su za le če nje oso ba s kar di o va sku lar­
nim obo lje nji ma (20,14%), in fek tiv nim i pa ra zit skim bo le sti­
ma (11,64%), bo le sti ma di ge stiv nog si ste ma (9,87%) i tu mo ri­
ma (8,48%), dok je naj ma nje sred sta va utro še no za le če nje simp­
to ma i pa to lo ških sta nja (0,95%), uro đe nih ano ma li ja (0,59%) 
i pe ri na tal nih sta nja (0,59%) (Gra fi ko ni 5 i 6). Tro ško vi zdrav­
stve ne za šti te po gla vi sta nov ni ka u 2006. go di ni iz no si li su 176 
evra, dok je udeo ukup nih tro ško va u BDP bio 4,86%.
Ukup ni tro ško vi zdrav stve ne za šti te u 2007. go di ni bi li su 
121 mi li jar du di na ra (mi li jar du i po evra; 2,25 mi li jar di do la­
ra). Po sma tra no po gru pa ma bo le sti, naj ve ća nov ča na sred stva 
iz dvo je na su za le če nje oso ba s kar di o va sku lar nim obo lje nji ma 
(19,42%), in fek tiv nim i pa ra zit skim bo le sti ma (11,67%), bo le­
sti ma di ge stiv nog si ste ma (9,53%) i tu mo ri ma (8,33%), dok je 
naj ma nje sred sta va utro še no za le če nje simp to ma i pa to lo ških 
sta nja (0,79%), uro đe nih ano ma li ja (0,49%) i pe ri na tal nih sta­
nja (0,37%) (Gra fi ko ni 7 i 8). Tro ško vi zdrav stve ne za šti te po 
gla vi sta nov ni ka u 2007. go di ni iz no si li su 201 evro, dok je udeo 
ukup nih tro ško va u BDP bio 5,12%.
Ukup ni tro ško vi zdrav stve ne za šti te u 2008. go di ni bi li su 
ne što ve ći od 142 mi li jar de di na ra (1,6 mi li jar di evra; 2,26 mi­
li jar di do la ra). Po sma tra no po gru pa ma bo le sti, naj ve ća nov­
ča na sred stva iz dvo je na su za le če nje oso ba s kar di o va sku lar­
nim obo lje nji ma (21,64%), bo le sti ma ner vnog si ste ma (8,73%), 
in fek tiv nim i pa ra zit skim bo le sti ma (10,53%), bo le sti ma di ge­
stiv nog si ste ma (10,40%) i tu mo ri ma (8,24%), dok je naj ma­
nje sred sta va utro še no za le če nje simp to ma i pa to lo ških sta nja 
(0,70%) i za le če nje oso ba s uro đe nim ano ma li ja ma (0,30%) 
(Gra fi ko ni 9 i 10). Tro ško vi zdrav stve ne za šti te po gla vi sta nov­
ni ka u 2008. go di ni iz no si li su 232 evra, dok je udeo ukup nih 
tro ško va u BDP bio 5,04%.
Ukup ni tro ško vi zdrav stve ne za šti te u 2009. go di ni bi li su ne­
što ve ći od 144 mi li jar de di na ra (1,63 mi li jar de evra; 2,16 mi­
li jar di do la ra). Po sma tra no po gru pa ma bo le sti, naj ve ća nov­
ča na sred stva iz dvo je na su za le če nje oso ba s kar di o va sku lar­
nim obo lje nji ma (18,87%), in fek tiv nim i pa ra zit skim bo le sti ma 
(11,20%), bo le sti ma di ge stiv nog si ste ma (9,26%) i tu mo ri ma 
(8,88%), dok je naj ma nje sred sta va utro še no za le če nje oso ba s 
uro đe nim ano ma li ja ma (0,33%) (Gra fi ko ni 11 i 12). Tro ško vi 
zdrav stve ne za šti te po gla vi sta nov ni ka u 2009. go di ni iz no si­
li su 200 evra, dok je udeo ukup nih tro ško va u BDP bio 5,10%.
Po sma tra no po gru pa ma bo le sti, naj ve ći tro ško vi zdrav stve­
ne za šti te u pe ri o du 2004–2009. go di ne iz dvo je ni su za kar di­
o va sku lar ne bo le sti, a naj ma nji za uro đe ne ano ma li je i pe ri na­
tal na sta nja. Ka da se po sma tra in deks ra sta fi nan sij skih sred­
sta va po gru pa ma bo le sti u tom pe ri o du, vi di se da su naj ve ća 
sred stva iz dvo je na za le če nje oso ba s kar di o va sku lar nim obo­
lje nji ma i da su se od 2004. do 2009. go di ne po ve ća la pet pu ta, 
dok su nov ča na sred stva za le če nje od bo le sti ner vnog si ste ma 
po ve ća na če ti ri pu ta (Gra fi kon 13).
Ana li za je po ka za la da su tro ško vi zdrav stve ne za šti te po gla­
vi sta nov ni ka ima li stal ni trend ra sta do 2008. go di ne, da bi se 
u 2009. uoči lo nji ho vo bla go sma nje nje (Ta be la 3).
Udeo ukup nih tro ško va za zdrav stve nu za šti tu u BDP od 
2004. do 2009. go di ne po ka zu je ten den ci ju ra sta sa 3,58% na 
5,10% (Ta be la 4).
DISKUSIJA
Pre gle dom is tra ži va nja ko ja se ba ve tro ško vi ma le če nja bo le sni­
ka [1­7] uvi de lo se da ve ći na stu di ja ob ra đu je sa mo po je di ne 
bo le sti [8­16], od no sno po je di nač ne po vre de [17], po re me ća je 
[18] ili sta nja [19­24]. Te ku ći tro ško vi zdrav stve ne za šti te pre­
ma glav nim gru pa ma bo le sti MKB pred vi đe ni su da bu du pri­
ka za ni sa mo u ta be li 6 SZR, kao deo NZS [25]. Mno gi ko ri sni­
ci ana li za NZS sma tra ju da je upra vo ta be la 6 u SZR, pod na zi­
vom „Tro ško vi za zdrav stve nu za šti tu po glav nim gru pa ma Me­
đu na rod ne kla si fi ka ci je bo le sti” (ka te go ri je MKB), naj va žni ja i 
naj ko ri sni ja do no si o ci ma zdrav stve ne po li ti ke. Prem da još ne 
po sto ji ja sno op šte pri hva će no me to do lo ško uput stvo za iz ra du 
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ta be le 6 (osim okvir nog, ko je je ko ri šće no i u ovom is tra ži va­
nju), me đu na rod na po re đe nja na osno vu ove ta be le, iako i da­
lje vr lo ret ka, ipak su po če la da se vr še [27]. Upra vo ta me đu­
na rod na upo re di vost je glav na pred nost ta be le 6. Njen ne do­
sta tak, me đu tim, je ste to što se pro ce ne tro ško va u raz li či tim 
ze mlja ma raz li ku ju u ob u hva tu i me to do lo gi ji pro ce ne, ta ko 
da se za sni va ju na ve li kom sku pu pret po stav ki, od no sno ve o­
ma ma lim uzor ci ma.
Ukup ni tro ško vi zdrav stve ne za šti te sta nov ni ka Sr bi je pre­
ma glav nim obo lje nji ma MKB su se od 2004. do 2009. go di ne 
po ve ća li sa oko 50 mi li jar di na sko ro 150 mi li jar di di na ra. Tro­
ško vi po gla vi sta nov ni ka iz ra že ni u evri ma ta ko đe su se to kom 
po sma tra nog pe ri o da po ve ća li, i to sa 84 evra 2004. go di ne na 
232 evra 2008. go di ne (sko ro tri pu ta), da bi se 2009. sma nji li 
na 200 evra, što se ob ja šnja va po sle di com osla blje ne vred no sti 
di na ra u od no su na evro u 2009. go di ni. Tro ško vi po gla vi sta­
nov ni ka iz ra že ni u do la ri ma to kom po sma tra nog pe ri o da be­
le že iste pro me ne.
Po sma tra no po gru pa ma bo le sti, naj ve ći tro ško vi zdrav stve­
ne za šti te u pe ri o du 2004–2009. go di ne u Sr bi ji iz dvo je ni su za 
le če nje oso ba s kar di o va sku lar nim obo lje nji ma, a to kom po sma­
tra nog vre men skog pe ri o da po ve ća li su se tri pu ta. To, u po re­
đe nju s ra stom fi nan sij skih sred sta va za dru ge gru pe bo le sti, 
pred sta vlja sred nji rast. Nov ča na sred stva za le če nje od kar di­
o va sku lar nih bo le sti u po me nu tom pe ri o du po ve ća la su se čak 
pet pu ta, za le če nje oso ba s obo lje nji ma ner vnog si ste ma i in­
fek tiv nim i pa ra zit skim bo le sti ma če ti ri pu ta, a za bo le sti mi­
šić no­ko šta nog si ste ma tri pu ta.
Ka da se re zul ta ti ovih tro ško va upo re de s na la zi ma iz Austra­
li je, Ka na de, Fran cu ske, Ne mač ke i Ho lan di je [27], vi di se da se 
i u tim ze mlja ma naj ve ća sred stva u okvi ru zdrav stve ne za šti­
te iz dva ja ju za kar di o va sku lar na obo lje nja, što je naj ve ro vat ni je 
po sle di ca da na šnjeg na či na ži vo ta. Za raz li ku od Sr bi je, gde se 
in fek tiv ne i pa ra zit ske bo le sti na la ze na dru gom me stu po po­
tro šnji u po sma tra nom pe ri o du, a pra te ih bo le sti di ge stiv nog 
si ste ma, bo le sti ner vnog si ste ma i tu mo ri, u po me nu tim ze mlja­
ma bo le sti ner vnog si ste ma se na la ze na dru gom me stu po uče­
šću fi nan sij skih sred sta va, a sle de ih bo le sti di ge stiv nog si ste­
ma, ko šta no­mi šić nog si ste ma i tu mo ri.
Ukup ni tro ško vi zdrav stve ne za šti te u Sr bi ji su se od 2004. 
do 2009. go di ne po ve ća li tri pu ta, a be le že br ži rast od ra sta op­
štih jav nih tro ško va za zdrav stve nu za šti tu u istim go di na ma, 
ko ji su se po ve ća li sa ne što vi še od 82 mi li jar de di na ra u u 2004. 
na sko ro 182 mi li jar de u 2009. go di ni [28]. Ta či nje ni ca go vo ri 
u pri log ve ćim iz dva ja nji ma u Re pu bli ci Sr bi ji za le če nje bo le­
sni ka to kom go di na, a sma nje nju ula ga nja u pre ven ci ju, uslu ge 
jav nog zdrav stva, zdrav stve nu ad mi ni stra ci ju, zdrav stve no osi­
gu ra nje i vr še nje funk ci ja ko je su u ve zi sa zdrav stve nom za šti­
tom. Udeo tro ško va zdrav stve ne za šti te u BDP u pe ri o du 2004–
2009. go di ne po ve ćao se sa 3,58% na 5,10%. U 2004. go di ni tro­
ško vi zdrav stve ne za šti te pre ma ka te go ri ja ma obo lje nja MKB 
u Sr bi ji či ni li su 54,1% ukup nih tro ško va za zdrav stve nu za šti­
tu, dok su u Ne mač koj i Ho lan di ji oni či ni li 62%, od no sno 60% 
ukup nih sred sta va ko ja se iz dva ja ju za zdrav stvo [27]. Po dat ke 
za osta le go di ne za dru ge ze mlje ni smo ima li.
ZAKLJUČAK
Is tra ži va nje je po ka za lo da su naj ve ća nov ča na sred stva u okvi­
ru tro ško va zdrav stve ne za šti te u pe ri o du 2004–2009. go di ne 
u Sr bi ji iz dvo je na za le če nje oso ba s obo lje nji ma kar di o va sku­
lar nog si ste ma, te da su se to kom šest po sma tra nih go di na po­
ve ća la tri pu ta.
